Results of the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Update after 21 years of follow-up

Galán, M. Lujan; Borda, Á. Páez; González, Luis Llanes; Cajigal, I. Romero; Sánchez, A. Berenguer

doi:10.1016/j.acuroe.2020.07.001

Cited by 1 publication

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, PSA screening has been found to lower the occurrence of PCa metastasis, and early treatment can be initiated through screening cases ( 24 , 25 , 28 , 32 , 34 , 40 , 41 ). Nevertheless, certain studies that have conducted extensive monitoring over a prolonged period have discovered that PSA screening does not provide any advantage in terms of survival ( 23 , 26 , 30 , 33 , 35 , 36 ) ( Table 2 ). This is primarily attributed to a decrease in long-term mortality caused by PCa.…”

Section: Resultsmentioning

confidence: 99%

“…Moreover, PSA screening facilitated prompt intervention for individuals in the screening group. Nevertheless, certain randomized experiments have failed to demonstrate a survival advantage of PSA screening in males diagnosed with PCa ( 26 , 30 , 35 , 43 ). With the rapid development of PCa treatment modalities, the long-term reduction of PCa mortality will weaken the impact of PSA screening on patient mortality, which may be the reason for the different results of PSA screening related studies.…”

Section: Discussionmentioning

confidence: 99%

“…Harmful consequences may arise as a result of screening in such instances. In addition, the above situation may also be due to regional differences, such as differences in the overall follow-up results of ERSPC study data and follow-up results in different regions ( 21 , 24 , 30 , 34 , 35 ). After all, the present therapeutic techniques for PCa are progressing swiftly, and the influence of varying degrees of treatment on the particular fatality rate of examined individuals is substantial.…”

Section: Discussionmentioning

confidence: 99%

“…The lower long-term PCa mortality rates found in the above study may be the most important factor contributing to these results. Subsequently, M. Lujan Galan et al (35) provided the latest results of the ERSPC Spanish Research Center follow-up after 21 years. No benefit of PCa screening in terms of overall survival or cancer-specific survival was found in the Spanish study portion of the 21-year follow-up.…”

Section: Basic Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

Application and optimization of prostate-specific antigen screening strategy in the diagnosis of prostate cancer: a systematic review

Zhang,

Tian,

Che

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Currently, prostate cancer (PCa) poses a global risk to the well-being of males. Over the past few years, the utilization of prostate-specific antigen (PSA) screening has become prevalent in the identification and management of PCa, which has promoted a large number of patients with advanced PCa to receive timely treatment and reduce the mortality. Nevertheless, the utilization of PSA in PCa screening has sparked debate, and certain research has validated the potential for overdiagnosis and overtreatment associated with PSA screening. Hence, in order to decrease the mortality rate of PCa patients and prevent unnecessary diagnosis and treatment, it is crucial to carefully choose the suitable population and strategy for PSA screening in PCa. In this systematic review, the clinical studies on PSA screening for the diagnosis and treatment of PCa were thoroughly examined. The review also delved into the effects and mechanisms of PSA screening on the prognosis of PCa patients, examined the factors contributing to overdiagnosis and overtreatment, and put forth strategies for optimization. The objective of this research is to offer valuable recommendations regarding the utilization of PSA screening for the detection and management of PCa.

show abstract